Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Pyxis Oncology, Inc.NASDAQ: PYXS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $23.27M (cash outflow) rose 10.0% year over year, ahead of the -14.2% change in trailing-twelve-month net income. Sequentially, it rose 28.5% from the prior quarter. Over 3 fiscal years it compounded at -13.0% a year.
Context
- Net income amounted to 574.5% of revenue in FY2025, up 95.6 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$71.23M (-10.5%) for the fiscal year ending Dec 2026, a slowdown from the +3.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$23.27M+28.5% QoQ
- Last fiscal yearDec 2025
- -$79.62M+3.0% YoY
- LTMMar 2026
- -$81.74M-14.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.0% | +59.2% | +49.3 pp |
| 1 year | +3.0% | -10.5% | -13.5 pp |
| 3-year CAGR | -13.0% | -10.0% | +3.0 pp |
| 5-year CAGR | -20.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (79.62M) USD
- Year-over-year change
- -3.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.62M) | -3.0% |
| FY2024 | 2024-12-31 | (77.33M) | -4.8% |
| FY2023 | 2023-12-31 | (73.79M) | +38.9% |
| FY2022 | 2022-12-31 | (120.72M) | -58.9% |
| FY2021 | 2021-12-31 | (75.98M) | — |
Net Income vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's LTM Mar 2026 net income of $81.74M is the 6th largest of the 10 companies compared; the peer median is $83.01M.
- Its year-over-year change of -14.2% is the 8th highest of 10, against a peer median of -6.4%.
- Net income amounts to 589.8% of revenue for PYXS, versus a peer median of 754.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $133.22M | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $116.64M | +37.7% | +37.1% | 319.6% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $83.01M | -21.5% | -9.9% | 36891.1% | |
| LTM Mar 2026 | $81.74M | -14.2% | -13.0% | 589.8% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| Peer median (excluding PYXS) | $83.01M | -6.4% | +11.0% | 754.4% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| Deferred Income Tax | 6.28M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.44M | 15.76M | 16.95M | 12.95M | 11.8M |
| Change in Working Capital | 6.68M | 4.5M | (11.66M) | (11.82M) | 1.94M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4.64M | (8.33M) | (3.51M) | 1.2M | 6.03M |
| Other Working Capital | 2.03M | 12.83M | (8.16M) | (13.02M) | (4.08M) |
| Other Non-Cash Items | 20.6M | 10.41M | (4.13M) | 15.56M | (2.14M) |
| Operating Cash Flow | (35.33M) | (89.34M) | (70.71M) | (57.67M) | (63.5M) |
| Capital Expenditures | (540K) | (6.4M) | (6.73M) | (237K) | (9K) |
| Acquisitions (Net) | (50K) | 0 | 6.66M | 0 | 0 |
| Purchases of Investments | (50K) | 0 | (196.83M) | (160.12M) | (107.01M) |
| Sales of Investments | 50.05K | 0 | 92.05M | 168.51M | 165.87M |
| Other Investing Activities | (50) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (590K) | (6.4M) | (104.85M) | 8.16M | 58.86M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 152.3M | 0 | 6.12M | 59.05M | 742K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 167K | 183K | (193K) | 280K | (148K) |
| Financing Cash Flow | 304.04M | 183K | 5.93M | 59.33M | 594K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 268.13M | (95.55M) | (169.63M) | 9.81M | (4.05M) |
| Free Cash Flow | (35.87M) | (95.73M) | (77.44M) | (57.91M) | (63.51M) |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.